Moderna Inc (NASDAQ: MRNA) and
Pfizer Inc. (NYSE: PFE)-
BioNTech SE – ADR (NASDAQ: BNTX) for their vaccine candidates.
Moderna and Pfizer-BioNTech received authorizations for their vaccine candidates in December.
Unlike the messenger RNA vaccines of Moderna and Pfizer-BioNTech, J&J s vaccine candidate uses a single-dose regimen and is an experimental viral vector vaccine that uses a weakened form of adenovirus to transport genetic material to trigger immune response.
J&J s vaccine candidate can remain stable for two years at -20 degrees Celsius, at least three months of which can be at temperatures of 2-8 degrees Celsius. The vaccines from Moderna and Pfizer, on the other hand, require cold-chain logistics to stay effective.